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(57)	 ABSTRACT
Antibodies have been developed against the different molecu-
lar forms of urokinase using synthetic peptides as immuno-
gens. The peptides were synthesized specifically to represent
those regions of the urokinase molecules which are exposed
in the three-dimensional configuration of the molecule and
are uniquely homologous to urokinase. Antibodies are
directed against the lysine 158-isoleucine 159 peptide bond
which is cleaved during activation from the single-chain
(ScuPA) form to the bioactive double chain (54 KDa and 33
KDa) forms of urokinase and against the lysine 135 lysine
136 bond that is cleaved in the process of removing the
alpha-chain from the 54 KDa form to produce the 33 KDa
form of urokinase. These antibodies enable the direct mea-
surement of the different molecular forms of urokinase from
small samples of conditioned medium harvested from cell
cultures.
12 Claims, 2 Drawing Sheets
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1
MOLECULAR-SPECIFIC UROKINASE
ANTIBODIES
ORIGIN OF THE INVENTION
The invention described herein was made at least in part in
the performance of work under a NASA contract and is sub-
ject to Public Law 96-517 (35 U.S.C. §200 et seq.). The
contractor has not elected to retain title to the invention.
FIELD OF THE INVENTION
The invention relates to compositions and methods of
using antibodies to analyze molecular forms of urokinase.
More particularly, a group of such antibodies, each of which
recognizes and selectively binds to one of several molecular
forms of urokinase, is used to detect, quantitate or purify
individual forms of urokinase. Species of urokinase that can
be analyzed using the compositions and methods of the inven-
tion include the inactive 54,000 dalton single chain form, the
bioactive, 34,000 dalton double-chain form and the bioactive
33,000 dalton form.
DESCRIPTION OF THE RELATED ART
Urokinase is one member of a class of proteins known as
fibrinolytic proteins. Other fibrinolytic proteins include strep-
tokinase and tissue plasminogen activator (tPA). These type
proteins aid in natural blood clot dissolution. Blood clot dis-
solution is an important therapy in the treatment of several
major debilitating and life threatening diseases including
myocardial infarction associated with heart attacks, stroke,
deep vein thrombosis and pulmonary embolus.
Urokinase is more specifically a serine protease. Its natural
substrate is plasminogen, which it converts to bioactive plas-
min. When plasmin comes in contact with the major struc-
tural component of blood clots called fibrin, the fibrin is
degraded into small fragments dissolving the clot.
Consequently, there is great interest in urokinase as a thera-
peutic agent. U.S. Pat. No. 4,873,083 discloses a fibrinolytic
composition employing an enzyme such as urokinase tissue
plasminogen activator and a surface active copolymer for the
treatment of thrombosis. U.S. Pat. Nos. 4,600,580, 4,673,
573, and 4,741,903 disclose chemically-modified forms of
urokinase that employ urokinase for fibrinolytic activity in
therapeutic applications. U.S. Pat. No. 4,791,068 discloses
the use of a polyclonal antibody system for detecting an
inhibitor of urokinase-type plasminogen activator and its use
in diagnostic assays.
For these reasons, there is also great interest in developing
more efficient methods of urokinase production. U.S. Pat. No.
4,889,808 discloses a method of enhancing the production of
a single chain urokinase by the addition of heparin and a cell
growth factor to culture medium of cells producing the
enzyme. The production levels were determined using poly-
clonal goat antisera which was not specific for active forms of
urokinase, but did allow crude detection of enhanced levels of
production.
Another approach is to isolate novel cell lines that produce
large quantities of this protein. Urokinase is known to be
secreted by kidney cells, some neoplastic tissues, as well as
embryonic cell line (Bernick and Kwann, J. Clin. Invest.
48:1740-1753 (1969); Barlow et al., Thrombosis Res., 32:29-
34 (1983)). Bernick and Kwann (J. Lab. Clin. Med. 70:650
(1967)) have reported that only 5-10% of the cells from
human embryonic kidney (HEK) produce plasminogen acti-
vators. Enhanced production can be achieved if cells produc-
2
ing urokinase are isolated from those cells that do not produce
urokinase. When a heterogeneous sample of renal cells is
separated under microgravity conditions by continuous flow
electrophoresis, several distinct subgroups canbe isolated. To
5 determine which subgroup most efficiently produces uroki-
nase, sensitive and specific assay methods that can detect the
various molecular forms and total urokinase are required.
Since urokinase is a cancer-specific protein, it is a marker
of neoplastic cell development, particularly in cases of inva-
io sion and metastasis where this enzyme can play an important
role. The role of urokinase in cancer has been discussed as it
relates to breast cancer (Schmitt et al., Blood Coagulation and
Fibrin. 1:695 (1990), urinary cancer (Hasui et al., Cancer
Res. 49:1067 (1989), and prostate cancer (Gaylis et al. J.
15 Urology 142:193 (1989)). Thus, sensitive and specific assays
are also needed which can be used to diagnose these condi-
tions.
Urokinase is synthesized as a single polypeptide of 431
amino acid residues. An amino terminal signal peptide of 20
20 amino acids (-20 to —1) is cleaved from the polypeptide as it
is processed during export from the cell, leaving a 411 amino
acid protein (1-411) that is called the urokinase zymogen or
single chain urokinase plasminogen activator (scuPA).
Urokinase zymogen has very little or no enzymatic activ-
25 ity. Activation of the urokinase zymogen involves cleavage of
the peptide bond between lysine 158 and isoleucine 159 and
the loss of lysine 158 to form the high molecular weight
(HMW) 54,000 dalton active enzyme (Verstraete and Collen,
Blood 67:1529-1541 (1986). Activation can also include (in
3o addition to 158-159 cleavage) cleavage of the bond between
lysine 135 and lysine 136 followed by loss of the amino
terminal 135 amino acids (the A chain") leaving an active
low molecular weight (33,000 dalton) enzyme. The non-en-
zymatic products of these cleavage events are rapidly
35 degraded. Activation and autodegradation of urokinase in a
cell culture can result in all three types of urokinase being
present in culture medium at one time.
To identify cell populations that express increased levels of
urokinase a quantitative measurements of all forms of uroki-
4o nase is necessary. To be of practical use, such assays must be
sensitive enough that urokinase production from small num-
bers of cells can be analyzed. Such assays must also be
relatively easy to perform so that large numbers of samples
containing as many as 5-10x10 4 cells/ml or more can be
45 tested.
Current urokinase assay methods are cumbersome. One of
the common procedures is the fibrin plate lysis assay. See,
e.g., U.S. Pat. No. 4,741,903; and, Lewis et al., "Problems in
the Bioassay of Products from Cultured HEK Cells: Plasmi-
5o nogen Activator" in Eukaryotic Cell Cultures: Basics and
Applications 172 Plenum Press, New York 1984. This assay
measures fibrinolytic activity. Test samples are incubated
with fibrin clots and the increase in the diameter of the clot
lysis zone is measured as a function of time. The rate of clot
55 disappearance is a measure of fibrinolytic activity. The detec-
tion limit for such assays is generally 10-15 LU./ml. Other
assays include the timed clot-lysis assay (Swank et al. Com-
puter Meth. Programs Biomed., 33:95-105 (1990)), 125I-la-
beled fibrinogen assay and colorimetric assays which use
60 synthetic chemical substrates, and the S-2444 assay, KabiV-
itrum, Sweden (Claeson et al., Haemostasis 7:76-78 (1978).
Assays such as these are also activity assays since they are
based on measurement of fibrinolytic activity. They are used
to detect and quantitate active urokinase but are incapable of
65 detecting the inactive zymogen.
Furthermore, existing assays are inadequate to detect small
quantities of uPA in very small (e.g. 10 µl) samples of culture
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medium or bodily fluids. Thus, such assays may not identify
potentially important cell lines that produce large quantities
of the urokinase zymogen (scuPA). The scuPA levels can be
approximated by preincubation of samples with plasmin
(which activates urokinase zymogen) followed by an activity
assay. However, additional steps in an already cumbersome
assay increase the variation in assay results. Moreover, it is
difficult to determine the amount of plasmin and hydrolysis
times needed to fully activate zymogen in all cases.
Inconsistent test results are frequently associated with
fibrin clot activity assays. For example, storage of samples
affects apparent activity, dose response curves are nonlinear,
and replicate cell cultures produce variable activities. More
importantly, protein diffusion is a factor affecting the appar-
ent activity of urokinase. The 33,000 dalton form diffuses
faster than the 54,000 dalton form increasing the apparent
activity relative to the 54,000 dalton form. Although the chro-
mogenic assay is not limited by protein diffusion, this assay is
not as sensitive as the fibrin clot assay. Sample composition
can greatly affect activity measurements, for example the
presence of inhibitors of urokinase may greatly reduce the
amount of activity measured for a given amount of enzyme.
Similarly, other non-urokinase fibrinolytic enzymes in the
sample may interfere by increasing the apparent activity.
Moreover, these assays are not sensitive enough to detect
urokinase produced from different subpopulations of small
numbers of cells.
Activity assays also are unable to distinguish between vari-
ous active forms of urokinase since they only measure total
fibrinolytic activity. This makes comparisons between
samples difficult. Use of a combination of assays, such as the
clot lysis assay in combination with the chromogenic assay,
can give approximate estimates of the ratios of the 54,000 and
the 33,000 dalton forms of urokinase. However, this is a
cumbersome and time-consuming procedure.
An alternative approach to analysis of the urokinase from
cell culture is to use quantitative immunological techniques
such as enzyme linked immunosorbent assays (ELISA) or
radioimmunoassays (RIA). Various murine and rabbit IgG
monoclonal antibodies are available against theA-chain (resi-
dues 1-135) or B-chain (residues 159-411) of urokinase (i.e.,
American Diagnostica, New York). These antibodies are
made from animals immunized with the major molecular
forms of urokinase. U.S. Pat. No. 4,474,756 discloses a
method of producing antibodies by immunization of animals
with a whole protein, such as human urokinase, after chemi-
cally crosslinking the protein to a polysaccharide. However,
since urokinase has more than 70% homology with trypsin
and significant homology to other serine proteases and tissue
plasminogen activator (tPA), specificity is a problem. There-
fore, non-specific antibodies such as these also bind to and
detect other serine proteases and fibrinolytic proteins, and
they do not give reliable quantitative estimates of urokinase in
samples.
Thus, compositions and methods are needed that can sen-
sitively and specifically quantitate urokinase in all its forms in
a sample. Assays are needed which overcome the cumber-
some aspects of existing methods and which produce less
variable results and which are not subject to interferences
from inhibitors which could contaminate sample prepara-
tions. Assays are needed which are specific for urokinase and
which distinguish between closely related proteins such as
tissue plasminogen activator or streptokinase or homologous
serine proteases that increase the "apparent' concentration of
urokinase observed in samples making existing assays inac-
4
curate. Lastly, assays are needed which are capable of mea-
suring the concentration of each form of urokinase in a
sample.
5	 SUMMARY OF THE INVENTION
In accordance with the present invention, polyclonal and
monoclonal antibody compositions are provided that can sen-
sitively and specifically quantitate urokinase in all its forms.
10 The compositions provided can be used in methods that are
convenient to perform, give reliable results, and are free from
interferences from enzyme inhibitors that could affect fibrin-
olytic activity measurements. The compositions are specific
for urokinase and will not detect closely related proteins such
15 as tissue plasminogen activator or homologous serine pro-
teases. Compositions provided with this invention can be
used to measure the concentration of each form of urokinase
even in a small sample.
Antibodies (polyclonal and monoclonal) were generated
Zo against urokinase by employing synthetic peptides as immu-
nogens. The antibodies that are generated by injecting an
immunogen into an animal are said to be "directed against'
that immunogen. Antibodies directed against immunogens
may bind to other molecules as well. Particularly, antibodies
25 directed against an immunogen may bind to other biological
macromolecules that contain the immunogen. In particular,
where as here the immunogen is a peptide which represents a
particular portion of the urokinase macromolecule, antibod-
ies directed against the peptide immunogen can bind to the
30 biological macromolecule urokinase in any of its forms
which contains the immunogen peptide sequence. If the
immunogen is found on one macromolecule or a subset of
macromolecules, and the antibody directed against that
immunogen binds preferentially to that macromolecule or
35 subset of macromolecules, the antibody is said to have "spe-
cific" binding for that macromolecule or subset of macromol-
ecules. "Specific" binding is merely a reflection of the fact
that the binding affinity of the antibody to macromolecules
containing the immunogen is higher than the binding affinity
40 of the same antibody to other molecules.
In certain aspects, the invention relates to an antibody
directed against a peptide whose sequence is chiefly derived
from the urokinase amino acid sequence (Seq. ID No. 16).
"Chiefly derived" for purposes of this invention means that
45 the sequence of the peptide is virtually identical to at least a
portion of a linear sequence of urokinase except for minor
alteration such as additional terminal residues or substitutions
of cysteine residues to prevent internal disulfide linkages (i.e.,
see Seq. ID No. 5 where cysteine-131 is replaced by a glycine
50 residue in the peptide to prevent disulfide formation with
cysteine-126).
The antibody is first characterized by its capability to spe-
cifically bind to urokinase. As further amplified in the claims,
the characteristic of specific binding to urokinase is such that
55 the antibody possesses a substantially lower binding affinity
to proteins other than urokinase than that it has for urokinase.
Importantly, this reduced binding affinity for non-urokinase
proteins includes those proteins as similar in amino acid
sequence to that of urokinase as is trypsin, a protein with a
6o high degree of sequence homology with urokinase.
One group of antibodies that meet this general description
will be antibodies which bind to the amino terminal end of
urokinase. The amino terminal end of the urokinase molecule
for purposes of the invention comprise urokinase amino acid
65 residues 1-135 of Seq. ID No. 16.
Among those antibodies which are specific for the amino
terminal end of the urokinase molecule will be those antibod-
US 7,541,159 B2
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ies directed against one or more of six specific peptides. These
peptides may be any one of a number of such peptides based
upon sequences of the amino terminal sequence of urokinase
such as: SNELHQVPSNCD (Seq. ID No. 1), RGKASTDT-
MGRPCLP (Seq. ID No. 2), CRNPDNRRRP (Seq. ID No.
3), RNPDNRRRPWC (Seq. ID No. 4), CMVHDGADGK
(Seq. ID No. 5) or MVHDCADGK (Seq. ID No. 6). In certain
instances, an original residue found in urokinase will be
altered for ease of synthesis which alteration does not mate-
rially affect the immunological response to the synthetic pep-
tide (e.g., instead of asparagine-10 as in urokinase, Seq. ID
No. 1 possesses an aspartate; instead of cysteine-131, Seq. ID
No. 5 possesses a glycine).
Another group of antibodies that meet this general descrip-
tion will be antibodies which bind to the carboxyl terminal
end of urokinase. The carboxyl terminal end of the urokinase
molecule for purposes of the invention comprise urokinase
amino acid residues 159-411 of Seq. ID No. 16.
Among those antibodies which are specific for the carboxy
terminal end of the urokinase molecule will be those antibod-
ies directed against one or more of six specific peptides. These
peptides may be any one of a number of such peptides based
upon sequences of the amino terminal sequence of urokinase
such as: YRRHRGGSVTYVC (Seq. ID No. 7), CFIDYP-
KKEDY (Seq. ID No. 8), SRLNSNTQGEMK (Seq. ID No.
9), SMYNDPQFGTSC (Seq. ID No. 10), LISHRECQQ-
PHYYGSEVTTKMLC (Seq. ID No. 11), or SHT-
KEENGLAL (Seq. ID No. 12).
Other antibodies which meet the general descriptions pro-
vided by the antibodies of the invention include antibodies
which can detect cleavage sites in urokinase. These antibod-
ies include an antibody which has a binding site that includes
the peptide bond between lysine 158 and isoleucine 159.
More specifically, such an antibody will be one which is
directed against one or more of two peptides selected from the
group of peptides comprising PRFKIIG (Seq. ID No. 13) or
RPRFKIIGGE (Seq. ID No. 14). These antibodies also
include an antibody which has a binding site that includes the
peptide bond between lysine 135 and lysine 136. More spe-
cifically, such an antibody will be one which has a lower
binding affinity for urokinase when no chemical bond exists
between lysine 158 and isoleucine 159. Similarly, such an
antibody will be one which has a lower binding affinity for
urokinase when no chemical bond exists between lysine 135
and lysine 136. The site defined by lysine 135 and lysine 136
is the natural cleavage site of the urokinase proenzyme and is
structurally exposed to cleavage, and thus is a likely natural
epitope region. This site is bridged by Seq. ID No. 17.
Particularly, in a preferred embodiment, an antibody
directed against the peptide sequence RPRFKIIGGE (Seq. ID
No. 14), with a binding affinity constant for the urokinase
zymogen of at least 1 x10 $ M-i , is disclosed which addition-
ally exhibits the binding affinity constant for urokinase lack-
ing a peptide bond between lysine 158 and isoleucine 159
decreased by at least ten-fold.
It is also possible to make multimers of peptides by
covalently linking one or more of peptides in Seq. ID Nos.
1-15. Thus, duplex peptides may easily be covalently linked
by disulfide linkages, as for example by making (102-111)-
(126-135), (59-73)-(103-113), (177-189)-(205-215). It is
also possible to cause a peptide to form an internal disulfide,
as for example in 319-341 (Seq. ID No. 11).
It will be recognized by one of skill in the art of making
antibodies against specific peptides, that such antibodies may
be derived from polyclonal sera. Alternatively, and in certain
aspects, preferably, the antibody of any of the embodiments
mentioned above may be a monoclonal antibody. More spe-
6
cifically, the monoclonal antibodies of the invention have
been given the designations: A3-E5-A7, A3-E5-B8, A3-E5-
G10, A3-E5-H12, A3-E5-B3, C2-A4-H4, C2-A4-F10,
C2-A4-F11, D4-A5-E7, D4-Cl-A5, D4-Cl-G4, D4-C6-A4,
5 D4-C6-A8, D4-C6-E12, D4-C6-F7 or D4-C6-G12. Hybri-
doma cell lines capable of producing such monoclonal anti-
bodies are also provided. While these specific monoclonal
antibodies and the hybridomas that produce them represent
the results of the particular experiments defined in greater
10 detail below, they are in merely exemplary in nature. Using
the sequences selected and disclosed in the invention, the
normally skilled practitioner may readily obtain antibodies
with the same characteristics as reported here and which will
function identically to those reported here by first obtaining
15 one or more peptides that "correspond to" one or more pre-
determined sequences of amino acids. The following three
paragraphs describe the meaning of the term "corresponding
to" and its derivatives in greater detail.
The peptides will be one of the group of peptides disclosed
20 in Sequence ID Nos. 1-15. It will be recognized, however, by
those of skill in the art that the catalysts described above and
those claimed in general may contain functionally equivalent
amino acid substitutions. The importance of the hydropathic
index of amino acids in conferring biological function on a
25 peptide is generally known by those of skill in the art. It has
been found by many researchers that certain amino acids may
be substituted for other amino acids having a similar hydro-
pathic index or score and still retain similar if not identical
biological activity. As displayed below, amino acids are
30 assigned a hydropathic index on the basis of their hydropho-
bicity and charge characteristics. It is believed that the relative
hydropathic character of the amino acid determines the sec-
ondary structure of the resultant peptide, which in turn defines
the interaction of the peptide with the substrate molecule. It is
35 proposed that biological functional equivalence may typi-
cally be maintained where amino acids are exchanged having
no more than a ±1 to 2 difference in the index value, and more
preferably within at I  difference.
40
AMINO ACID	 HYDROPATHIC INDEX
Isoleucine 4.5
Valine 4.2
45	 Leucine 3.8
Phenylalanine 2.8
Cysteine/Cystine 2.5
Methionine 1.9
Alanine 1.8
Glycine —0.4
50	
Threonine —0.7
Tryptophan —0.9
Serine —0.8
Tyrosine —1.3
Proline —1.6
Histidine —3.2
Glutamic Acid —3.5
55	 Glutamine —3.5
Aspartic Acid —3.5
Asparagine —3.5
Lysine —3.9
Arginine —4.5
60
Thus, for example, isoleucine, which has a hydropathic
index of +4.5, can be substituted for valine (+4.2) or leucine
(+3.8), and might still obtain a peptide having similar bio-
logical activity. Alternatively, at the other end of the scale,
65 lysine (-3.9) can be substituted for arginine (-4.5), and soon.
Accordingly, these amino acid substitutions are generally
based on the relative similarity of R-group substituents, for
US 7,541,159 B2
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example, in terms of size, electrophilic character, charge, and
the like. In general, although these are not the only such
substitutions, the preferred substitutions which take various
of the foregoing characteristics into consideration include the
following:
8
each of the bioactive and inactive forms of urokinase detect-
able using the four antibodies included in the kit.
BRIEF DESCRIPTION OF THE DRAWINGS
ORIGINAL RESIDUE	 EXEMPLARY SUBSTITUTIONS
alanine glycine; serine
arginine lysine
asparagine glutamine; histidine
aspa.rtic acid glutamic acid
cysteine serine
glutamine asparagine
glycine alanine
histidine asparagine; glutamine
isoleucine leucine; valine
leucine isoleucine; valine
lysine arginine; glutamine; glutamic acid
methionine leucine; tyrosine
serine threonine
threonine serine
tryptophan tyrosine
tyrosine tryptophan; phenylalanine
valine isoleucine; leucine
In addition to the compositions provided by the invention,
methods are disclosed which utilize the anti-urokinase anti-
body compositions in a variety of ways. Thus, in one embodi-
ment, a method of detecting urokinase zymogen in a sample
is provided. This method comprises standard plate assays
including solid phase plate radioimmunoassay or enzyme
linked immunoassays (ELISA). Another method made pos-
sible by the anti-urokinase antibody compositions of the
invention include detecting urokinase associated with the
surface of a cancer cell. This method comprises using the
antibodies of the invention to detect urokinase levels in a cell
population, which levels are correlated to DNA content for
evaluation of potential of tumor cells.
For whateverpurpose the quantitation is accomplished, the
technique will be similar in its use of the peptides of the
invention. Thus, Seq. ID Nos. 1-15 can be used to generate
immunological compositions capable of recognizing the
urokinase zymogen. The same is true of a peptide comprising
residues 135 and 136 of Seq. ID No. 16. When the same
battery of immunological compositions is used against the
high molecular form of urokinase which lacks the 158-159
peptide bond, each such composition will bind the high
molecular weight form of urokinase except immunological
composition derived from Seq. ID Nos. 13 and 14, thusly
providing a test to distinguish the inactive zymogen from the
active high molecular weight form of urokinase. The same
battery of immunological compositions is useful in distin-
guishing the low molecular weight form will not efficiently
bind immunological compositions derived from Seq. ID Nos.
1-6, 13-14 or from a peptide comprising residues 135 and 136
of Seq. ID No. 16.
Diagnostic kits for detecting the presence and quantity of
urokinase in a sample are also provided. Such kits comprise
effective amounts of the antibodies which individually bind to
the amino terminal end of urokinase, the carboxyl terminal
end of urokinase, the binding site that includes the peptide
bond between lysine 158 and isoleucine 159, and the binding
site that includes the peptide bond between lysine 135 and
lysine 136. Additionally, each such antibody includes an indi-
cating group capable of detecting binding of the antibody to a
target molecule and standards of an effective concentration of
FIG. 1: Standard curve for Run 4 Day 12 supernatants
radioimmunoassay.
FIG. 2: Bar graph comparing amount of scuPA in the Run
4 Day 12 supernatants using two prior art methods (S-2444
10 and MCLA) and methods of invention (MSA-RIA).
DESCRIPTION OF PREFERRED
EMBODIMENTS
15 With respect to the inactive form of urokinase (See Seq. ID
No. 16), activation of the zymogen involves cleavage of the
peptide bond 15 8-15 9 and the loss of Lys-158. An active form
of the enzyme is produced which has the sequence 1-157 (A
chain) linked to sequence 159-411 (B chain) by a disulfide
20 bond between Cys-148 and Cys-249. Another active form of
the enzyme has sequence 136-157 (Al chain) linked to
sequence 159-411 (B chain). The various regions selected for
synthesis correspond to sequences 1-12 (Seq. ID No. 1),
59-73 (Seq. ID No. 2), 102-111 (Seq. ID No. 3), 103-113
25 (Seq. ID No. 4),126-135 (G at 131) (Seq. ID No. 5),127-135
(Seq. ID No. 6), 177-189 (Seq. ID No. 7), 205-215 (Seq. ID
No. 8), 222-233 (Seq. ID No. 9), 319-330 (Seq. ID No. 10),
319-341 (Seq. IDNo. 11), 401-411 (Seq. IDNo. 12),155-161
(Seq. ID No. 13) and 154-163 (Seq. ID No. 14). In addition,
30 the following peptide pairs will be linked by disulfide bonds:
(59-73), (102-111)-(126-135, G131) and (177-189)-(205-
215). The covalent structures of the peptides that have been
(or are being) synthesized are shown in Table 1. The single
letter notations of the amino acids are: A, alanine; C, cysteine;
35 D, aspartic acid; E, glutamic acid; F, phenylalanine; G, gly-
cine; H, histidine; I, isoleucine; K, lysine; L, leucine, M,
methionine; N, asparagine; P, proline; Q, glutamine; R, argi-
nine; S, serine; T, threonine; V, valine; W, tryptophan; Y,
tyrosine.
40
Peptide Immunogen Synthesis
The peptides used for certain particular examples of the
invention correspond to the Sequence ID Nos. 1-6. These
peptides, as well as other peptides produced using the meth-
45 ods of the invention, are synthesized either by t-butyloxycar-
bonyl (t-Boc) on a phenylacetamidomethyl (PAM) resin or by
9-fluorenmethylcarbonyl (Fmoc) amino acids on a benzylox-
yvbenxyl alcohol resin as described elsewhere (McCormick
and Atassi, Biochem. J., 224:9950-10000 (1984); Mulac-
50 7ericevic andAtassi, J. Prot. Chem, 6:365-373 (1987); Atassi
et al., Proc. Nad. Acad. Sci. USA, 88:3613 (1991), together
with methods for purification and characterization of the pep-
tides.
Peptide immunogens can be synthesized chemically by the
55 well known methods discussed above. They can also be iso-
lated by purification after proteolysis of individual forms of
urokinase. Particular care must be given to the choice of
protease used in the latter method so that desired epitomes are
not destroyed.
60 To avoid generating antibodies that cross react with other
known proteins peptide immunogen sequences are selected
which are unique to urokinase. To determine which
sequences are unique to urokinase, the urokinase sequence
can be aligned with other proteins whose sequences are
65 known. Many of these protein sequences can be found in data
bases and convenient computer programs can be enlisted to
perform a homology search. Such searches may be accom-
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plished using the FAST-DB (Fast Pairwise Comparison of
Sequences Release 5.4) sequence homology searching pro-
gram as provided by Intelligenetics, Inc., 700 East El Camino
Real, Mountain View, Calif. 94040. The searches may be
conducted in the publicly-available sequence databases
PIR39 and Swiss-Prot 28.
Fourteen peptides were prepared for use as immunogens.
Peptides derived from the amino terminal end of the uroki-
nase protein, including residues 1 through 135, were used to
generate antibodies specific for the  chain of urokinase. Six
peptides represent areas present only in the zymogen and high
molecular weight forms of the enzyme. The low molecular
weight form does not contain these areas due to the loss of the
first 158 residues after enzymatic degradation. As a result,
antibodies directed against these peptides only bound the
high molecular weight forms of urokinase, providing compo-
sitions for simple discriminating assays. The six peptides that
were found useful in generating the  chain specific antibod-
ies include: SNELHQVPSNCD (Seq. ID No. 1), RGKAST-
DTMGRPCLP (Seq. ID No. 2), CRNPDNRRRP (Seq. ID
No. 3), RNPDNRRRPWC (Seq. ID No. 4), CMVHD-
GADGK (Seq. ID No. 5) and MVHDCADGK (Seq. ID No.
6).
Peptides derived from the carboxyl terminus of urokinase
including residues 159-411 were used to generate antibodies
specific for the B chain of urokinase also known as the low
molecular weight (LMW) form or 33,000 dalton form of
urokinase. Six peptides that found use in generating B chain
specific antibodies include: YRRHRGGSVTYVC (Seq. ID
No. 7), CFIDYPKKEDY (Seq. ID No. 8), SRLN-
SNTQGEMK (Seq. ID No. 9), SMYNDPQFGTSC (Seq. ID
No. 10), LISHRECQQPHYYGSEVTTKMLC (Seq. ID No.
11), and SHTKEENGLAL (Seq. ID No. 12).
Other especially useful peptides encompass the peptide
bond between lysine 158 and isoleucine 159. These peptides
were used to generate antibodies that bind to the urokinase
zymogen, also known as the single chain urokinase plasmi-
nogen activator (ScuPA). Two peptides that found use in
generating urokinase zymogen specific antibodies include:
PRFKIIG (Seq. ID No. 13) and RPRFKIIGGE (Seq. ID No.
14). Additional compositions may be considered as immuno-
gens in the preparation of antibodies useful for this invention,
for example carbohydrates linked to urokinase or other bio-
chemical or chemical modifications to the urokinase polypep-
tide chain or peptide sequences homologous to urokinase
sequences. Additionally, combinations of the peptides dis-
cussed above, as mixtures, and covalently attached in groups
of two or more may be useful.
Immunization
Peptides may be used for immunization directly, after for-
mulation or after conjugation to a carrier molecule. Examples
of formulations for peptide immunogen injection include Fre-
und's adjuvant. Carrier molecules that can be used to conju-
gate to peptide immunogens include bovine serum albumin
(BSA), lysozyme, and polysaccharides such as dexetrins.
Antisera Against Peptides
Antibodies against the synthetic peptides were raised in
mice by two methods (a) immunization by peptide-protein
conjugates: Mice were injected and boosted with the peptide-
SuBSA conjugate (50 µg per mouse) as an emulsion in com-
plete Freund's adjuvant in the footpads and subcutaneously in
the neck. Serial bleedings from 10 days prior, up to 230 days
after, the first injection will be collected and studied sepa-
rately. (b) Immunization with free peptide: In view of the
finding (Young et al., Immunol. Commun., 11:9-16 (1982))
that small synthetic peptides (6 residues or larger), when
immunized in their free form in complete Freund's adjuvant,
will stimulate an in vivo antibody response, peptides were
injected into mice in their free form (i.e., without coupling to
carrier). Each animal received peptide (25-50 µg per mouse)
5 as an emulsion in complete Freund's adjuvant distributed into
three sites as above. The animals were boosted with similar
doses 3 weeks after the first injection and thereafter monthly.
Serial bleedings from 10 days before, up to 200 days after, the
initial injection were studied separately.
10 Monoclonal Antibody Preparation
Methods for preparing monoclonal antibodies are well
established. See for example, Monoclonal Antibodies, eds.
Roger H. Kennett, Thomas J. McKeam, Kathleen B. Bechtol,
15 Plenum Press, New york, 1980; Nature (1975) 256:495-497.
The discovery (Young et al., (1982), id.) that synthetic
peptides will evoke antibody formation when used as immu-
nogens in their free form (i.e., without coupling to a carrier)
was exploited to prepare monoclonal antibodies with prese-
20 lected submolecular binding specificities to desired protein
regions (Schmitz, et al., Mol. Immunol., 19:1699-1702
(1982)). Peptides representing antigenic sites as well as syn-
thetic peptides representing surface regions that are not anti-
genic when the whole molecule is used as an immunogen
25 have been shown to produce antisera and subsequently mono-
clonal antibodies of preselected specificities (Schmitz, et al.,
Mol. Immunol., 20:719-726 (1983); Schmitz, et al., Mol.
Immunol., 12:161-175 (1983)).
Mice were immunized as above with a given synthetic
30 peptide (25-50 µg) in complete Freund's adjuvant and
boosted and test-bled at 3 week intervals until high antibody
titer was obtained in the test sera. Somatic cell fusions, hybri-
doma selection, limiting dilution cloning and subcloning, and
hybrid cell expansion were performed as described by
35 Schmitz et al. (Schmitz, et al., (1982) id.). Expanded sub-
clones were also injected into BALB/cBy7 mice (2x10 6 cells/
1.0 ml. fresh tissue culture media) that had been primed with
pristane (Sigma Chemical Co., St. Louis, Mo.). Ascites fluid
was collected, clarified and stored frozen at —20° C. until
40 screened for the presence of hybridoma antibodies.
Essentially the peptide immunogen is injected into an ani-
mal, then cells producing a useful composition are immortal-
ized and identified. Additional injections at timed intervals
may be used to increase the titer and avidity of the antibodies
45 in the serum. Polyclonal antibodies are prepared by removing
serum from these animals. Usually mice are the animal of
choice and spleen cells that produce antibodies are immortal-
izedby fusion to immortal mouse myeloma cells, for example
SP/2 or 653 cells. Other animals may also be used to generate
50 monoclonal antibodies including chickens or goats or any
animal with cells that produce an antibody molecule such that
the productive cell can be immortalized. Immortalization of
the producing cell is needed to produce a stable starting
material for the repeated production of the useful monoclonal
55 antibodies when required. Techniques for cell immortaliza-
tion include: fusion to immortal cells where the fused cell
product continues to express the useful immunoglobulin, or
viral infection may be used to immortalize productive cells.
Screening for antibodies with desired specificity can be
60 performed using any of a variety of methods. In a Western blot
method, protein of interest is immobilized on a solid surface,
such as nitrocellulose, can be incubated with hybridoma
supernatants or serum and 1251-labelled anti-mouse IgG, fol-
lowing removal of the incubation medium and washing of the
65 surface, radioactivity that is bound to the surface is measured.
Another method involves addition of the original peptide
immunogen to the well of a growing hybridoma culture and
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looking for blebs or disruptions in the growing cell mono-
layer. Disruptions are an indication that the hybridoma is
producing antibodies against the added immunogen.
Monoclonal antibodies have been prepared which are of
use in the present invention. Murine monoclonal antibodies
produced from clones A3-E5-A7, A3-E5-B8, A3-E5-G10,
A3-E5-H12, A3-E5-B3, A3-E5-Dl were produced against
the peptide immunogen PRFKIIG (Seq. ID No. 13). Murine
monoclonal antibodies produced from clones C2-A4-H4,
C2-A4-F10, C2-A4-FI I were produced against the peptide
immunogen RPRFKIIGGE (Seq. ID No. 14). Murine mono-
clonal antibodies produced from clones D4-A5-E7, D4-Cl-
A5, D4-Cl-G4, D4-C6-A4, D4-C6-A8, D4-C6-E12, D4,
C6-F7 and D4-C6-G12 were directed against the peptide
RPRFKIIGGE (Seq. ID No. 14) after it was chemically con-
jugated to bovine serum albumin.
Polyclonal Antibody Preparation
Essentially any animal that generates an immune response
could be used to generate useful polyclonal antibodies for thi s
invention. Animals commonly used include goats, sheep, rats,
rabbits, chickens and cows. Particular polyclonal antibody
preparations that find use in this invention were prepared
from mice and rabbits. Peptides that were of use in generating
antibodies against the low molecular weight form of uroki-
nase include YRRHRGGSVTYVC (Seq. ID No. 7), CFI-
DYPKKEDY (Seq. ID No. 8), SRLNSNTQGEMK (Seq. ID
No. 9), SMYNDPQFGTSC (Seq. ID No. 10), LISHRECQQ-
PHYYGSEVTTKMLC (Seq. ID No. 11), SHTKEENGLAL
(Seq. ID No. 12). These antibodies were chemically conju-
gated to BSA prior to injection. Chemical conjugation is not
always required. For example, useful antibodies were also
generated against the free peptides CFIDYPKKEDY (Seq. ID
No. 8), SRLNSNTQGEMK (Seq. ID No. 9), and SMYND-
PQFGTSC (Seq. ID No. 10) in mice. Other peptides that
produced polyclonal antibodies of use in this invention
include SNELHQVPSNCD (Seq. ID No. 1), RGKASTDT-
MGRPCLP (Seq. ID No. 2), CRNPDNRRRP (Seq. ID No.
3), RNPDNRRRPWC (Seq. ID No. 4), CMVHDGADGK
(Seq. ID No. 5) and MVHDCADGK (Seq. ID No. 6). Poly-
clonal antibodies are conveniently prepared by injecting ani-
mals with immunogen as described above.
Serum is removed from the animal and prepared by con-
ventional techniques as described above. A blood clot is
formed spontaneously. The clot is removed and the remaining
serum can be purified further. The IgG molecules can be
purified away from the serum by affinity chromatography to
immobilized proteinA or protein G. Proteins that lack an IgG
heavy chain constant region will not bind to this affinity resin
and will be separated from the desired polyclonal IgG anti-
bodies. Immobilized urokinase may also be used to purify the
desired antibody away from other serum proteins. Elution of
the bound antibodies can be achieved by using mild denatur-
ants such as 2 molar guanidine hydrochloride or extremes of
pH such as a glycine-HCl buffered solution at pH 2.5.
The antibody preparations are then screened. Immune IgG
preparations or protein  were radiolabeled with 1251 (Amer_
shamCorp., Arlington Heights, Ill.) using the chloramine-T
method (Hunter et al., Nature, 194:495-496 (1962)).
Unbound 1251 was separated from the radiolabeled sample by
gel filtration on Sephadex G-25 (Pharmacia Fine Chemicals,
Piscataway, N.7.). Protein-associated 1251 was assayed by
precipitation with 10% (v/v) trichloracetic acid.
Polyvinylchloride protein assay plates (Costar, Cam-
bridge, Md.) were incubated for 3 hours at 37° C. with excess
(1.5 µg in 50 µg of PBS/well) test and control antigens,
washed extensively with PBS, and blocked with 1% BSA in
12
PBS (100 ld/well) for 1 hr at 37° C. to prevent non-specific
binding of subsequent reagents. After washing, the plates
were used for binding antibody.
Sera, culture supernatants and clarified ascites fluids were
5 screened for anti-UK antibodies using a solid phase RIA
described by Sakata and Atassi (Mol.Immunol., 18:961-967
(1981) as modified by Schmitz et al. ((1982) id.). This assay
was also used to determine antibody binding specificities to
peptides. Briefly, RIA plates that had been coated with the
10 appropriate test antigens (various forms of UK or peptide
conjugates) were incubated for 3 hours at 37° C. with an
antibody preparation (50 µl/well) appropriately prediluted in
PBS-BSA so as to maximize specific binding. The plates
were subsequently washed with PBS and amplified with
15 excess (1:1000 dilution of the stock reagent in PBS-BSA)
rabbit anti-mouse IgG+IgM antisera (Litton Bionetics, Kens-
ington, Miss.) for 2 hrs at 37° C. After washing, the plates
were developed with excess (2.Ox 10 5 cpm in 50 µl PBS-BSA/
well) 125I-labelled protein A for 2 hrs at room temperature,
20 washed, and then separated into individual wells that are
counted in a gamma counter (Beckman Instruments, Inc.,
Irvine, Calif.). Results are corrected for nonspecific (0.1-2%)
binding detected in control wells not coated with test antigen
but blocked with BSA.
25 When peptide-SuBSA conjugates are the immunizing anti-
gens then antibody responses were analyzed by peptide-
lysozyme (not succinyl lysozyme) conjugates since lysozyme
and SuBSA do not cross-react immunochemically. Correc-
tion for non-specific binding is derived from binding to
30 lysozyme control. When the free peptides were the antigens
then antibodies were analyzed on peptide-SuBSA conjugates
and employing lysozyme and SuBSA as controls.
One of the novel aspects of these antibodies is their speci-
35 ficity for binding only to urokinase and not to other related
proteins such as trypsin or TPA.
Other Methods of Using the Compositions
Analysis of Separated Kidney Cells
40 Cell separation in microgravity is one of the significant
new applications of space technology to basic and clinical
medical research. Separations are more effective in micro-
gravity conditions due to the lack of sedimentation and
absence of other limitations imposed by physical forces. Kid-
45 ney cells have been used as a model for their separation by
continuous flow electrophoresis and other methods under
microgravity conditions. After the cells are separated, it is
important to determine their purity, viability and physiologi-
cal performance. The compositions and methods provided in
50 this invention have been used to determine these parameters.
Cancer Diagnosis and Monitoring
This invention provides methods and compositions that are
useful in the diagnosis and monitoring of tumors, which
55 produce urokinase (such as breast, prostate and adenosar-
coma). Analysis can be performed on biological fluids such as
blood serum, urine, saliva and semen as a way of detecting
urokinase and identifying cancer development or progress.
The cells are removed from the serum by centrifugation and
60 the soluble protein fraction assayed by a sensitive ELISA or
RIA technique as previously described.
Immunohistochemical methods can be used to identify the
presence of urokinase in tumor biopsy specimens. For
example, the tumor tissue can be quick frozen, sections can be
65 cut and fixed with acetone on glass slides, the sections can be
treated with normal serum to reduce non-specific anti-uroki-
nase antibody binding. The antigen can be detected by expo-
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sure to unlabeled primary antibody and a labeled second The polyclonal antisera were labelled with 1251 as
antibody. Cells from five needle biopsies may be similarly described above and their binding to the peptide-lysozyme
tested for uPA. conjugate and to the low molecular weight urokinase was
Purification of Individual Forms of Urokinase determined. Results represent pools of antisera from 3 mice
Antibodies are relatively stable macromolecules they can 5 each and varied ±1.7% or less.
be immobilized on solid supports to produce useful chroma- TABLE 1
tography media. The unique specificity of an antibody makes
the chromatography media extremely specific for particular Antibodies against UK Peptides of the B chain bind to both correlative
molecules and facilitates the purification of these molecules peptide-lysozyme conjugates and to low molecular weight Urokinase,
from complex mixtures. A variety of methodologies can be
10
with similar affinity.
used to immobilize antibodies on solid supports. Antibodies 125I-Antibodies bound (A eom) to
useful to this invention can be used in this way to provide
chromatography resin that will allow the purification of each Peptide-lysozyme	 Low M.W.
form of urokinase. Antigen	 conjugate	 U.K.15
The following examples are offered as illustrations and are peptide 177-189 (Seq. ID No. 7)	 43,940	 45,570
not meant to limit the scope of the invention. peptide 205-215 (Seq. ID No. 8)	 42,490	 44,310
peptide 222-233 (Seq. ID No. 9)	 45,570	 47,520
EXAMPLES peptide 319-330 (Seq. ID No. 10) 	 49,540	 51,090peptide 319-341 (Seq. ID No. 11) 	 42,590	 43,510
20 peptide 401-411 (Seq. ID No. 12) 	 41,060	 42,520
Example I
Synthesis and Purification of Peptide Immunogens It was similarly shown that certain of the C-terminal
domain peptides demonstrated binding to all forms (LMW
A total of 14 peptides corresponding to different areas of 25 and HMW) of urokinase with affinities comparable to the
the urokinase molecule have been synthesized, purified and binding exhibited by the correlative free peptide.
characterized. A general discussion of the chemical synthesis
of peptides, their purification and characterization can be TABLE 2
found in the Description of Preferred Embodiments above. Antisera (polyclonal) Against Peptides in the common C-terminal
30 Domain Bind All Forms of Urokinase.
SPECIFIC BINDING (CPM)
Peptides Synthesized for Antibody Development Binding to	 Binding to	 Urokinase
Antigen	 Mouse No.	 Free Peptide	 LMW	 HMW
(1)	 1-12	 SNELHQVPSNCD	 (Seq.	 ID No.	 1)
Peptide 205-215	 1	 50033	 30761	 44755
(2)	 59-73	 RGKASTDTMGRPCLP	 (Seq.	 ID No.	 2) 35 (Seq. ID No. 8)	 2	 24190	 10563	 17550
3	 40467	 23841	 36670
(3)	 102-111	 CRNPDNRRRP	 (Seq.	 ID No.	 3) Peptide 222-233	 1	 36101	 17354	 26819(Seq. ID No. 9)	 2	 52730	 19853	 27951
(4)	 103-113	 RNPDNRRRPWC	 (Seq.	 ID No.	 4) 3	 25601	 10635	 17033
Peptide 319-330	 1	 14863	 10923	 11699
(5)	 126-135	 CMVHDGADGK	 (Seq.	 ID No.	 5) 40 (Seq. ID No. 10)	 2	 24374	 9617	 168223	 9183	 5168	 6833
(6)	 127-135	 MVHDCADGK	 (Seq.	 ID No.	 6)
(7)	 177-189	 YRRHRGGSVTYVC	 (Seq.	 ID No.	 7) The same test were run on N-terminal domain peptides
with similar results against whole urokinase.
(8)	 205-215	 CFIDYPKKEDY	 (Seq.	 ID No.	 8) 45
TABLE 3
(9)	 222-233	 SRLNSNTQGEMK	 (Seq.	 ID No.	 9)
Antisera (polyclonal) Binding to Urokinase Peptides and to Urokinase.(10)	 319-341	 SMYNDPQFGTSC	 (Seq.	 ID No.	 10) SPECIFIC BINDING
(11)	 282-293	 LISHRECQQPHYYGSEVTTKM (Seq. 	 ID No.	 11) 50 Binding
LC to	 Binding
Free	 to
(12)	 401-411	 SHTKEENGLAL	 (Seq.	 ID No.	 12) Antigen	 Mouse No.	 Peptide	 Urokinase
(13)	 155-161	 PRFKIG	 (Seq.ID No.	 13) Peptide 1-12	 1	 30740	 8726
55 (Seq. ID No.1	 2	 36318	 3644(14)	 154-163	 RPRFKIIGGE	 (Seq.	 ID No.	 14) 3	 27112	 3554
Peptide 59-73	 1	 33478	 3554
(Seq. ID No. 2)	 2	 19784	 3294
3	 25172	 3358
Example 11 Peptide 102-111	 1	 25992	 10414
(Seq. ID No. 3)	 2	 21596	 6482
Preparation of Polyclonal Antibodies
60 3	 36336	 8988
Peptide 103-113	 18876	 7220
(Seq. ID No. 4)	 2	 10964	 8708
A general description of the method used to prepare poly- 3	 12656	 9788
clonal antibodies can be found in Description of the Preferred Peptide 126-135	 1	 35798	 3784(Seq. ID No. 5)	 2	 15668	 2016
Embodiments above. Antisera obtained in this way binds very 65 3	 21434	 3460
strongly to the immunizing peptides as shown by solid phase
RIA.
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Example III
TABLE 4-continued
Preparation of Monoclonal Antibodies
Antibody Titer of Urokinase Monoclonals (cpm/min of RIA)
A general description of the method used for the prepara- 5
tion of monoclonal antibodies can be found in Description of
Preferred Embodiments. Monoclonal antibodies were pre-
pared with the capacity to discriminate between the three
common molecular forms of urokinase. Three groups of anti-
bodies were developed by the use of synthetic peptides which to
represent the areas described above. The first group of pep-
tides consisted of areas present both in prourokinase and high
molecular weight urokinase, but absent in the low molecular
weight form. These six peptides were synthesized, cleaved,
purified and injected into BALB/c mice for the preparation of 15
peptide-specific antisera. Spleen cells from these mice were
fused with SP/2 myeloma cells in order to prepare mono-
clonal antibodies. In addition, six peptides representing areas
present in all three molecular forms were made. Monoclonal
antibodies raised against these peptides bound all forms of 20
urokinase but not other serine proteases.
For the differential recognition of prourokinase from high
molecular weight urokinase, specific monoclonal antibodies,
binding to the area of cleavage, were developed. Two peptides
were constructed which represent the area around the single 25
peptide bond that is cleaved in the activation process (i.e.,
conversion of the zymogen into the active enzyme). Mono-
clonal antibodies specific for this area only bound to uroki-
nase zymogen but not high molecular weight urokinase.
After injection of the peptides into outbred mice, and 30
fusion of their spleen cells, 17 monoclonal antibodies were
selected for their specificity to one of the peptides (peptide
154-163, Seq. ID No. 14). A table showing the results of this
screening is shown at Table 4, below.
These monoclonals were tested for binding to the different 35
forms of urokinase by the western blot method. The nitrocel-
lulose paper was incubated with cell culture supernatants and125I-labelled anti-mouse IgG. Three of the monoclonals
showed specific binding to single chain urokinase. The clones
involved were expanded and the monoclonal antibodies puri- 40
lied for further characterization and testing.
Several monoclonal antibodies were also made in mice and
were then tested for specificity to ScuPA, the A-chain,
B-chain the cleavage bonds at Lys-158-Ile-159, the loss of
Lys-158 and the cleavage bond at Lys-135-LysI36 during 45
activation. Additional murine monoclonal antibodies and rab-
bit anti-urokinase monoclonal antibodies were made and
tested.
TABLE 4
Antibodv Titer of Urokinase Monoclonals (com/min of RIA
Clone No.
BSA-
Urokinase
Peptide
BSA-Non
Sense
Peptide
BSA Only
Blank
A3-E5-A7 71,813 803 901
A3-E5-B8 47,816 1,321 876
A3-E5-G10 58,503 1,454 1,311
A3-E5-H12 85,240 1,138 1,158
A3-E5-B3 59,674 871 821
A3-E5-D1 36,729 934 877
C2-A4-H4 7,633 1,855 928
C2-A4-1`10 40,659 3,053 1,448
C2-A4-F11 91,196 6,987 1,726
D4-A5-E7 4,962 1,393 1,430
D4-Cl-A5 25,631 1,579 1,355
D4-Cl-G4 90,645 3,410 1,497
D4-C6-A4 72,303 1,101 1,045
BSA-	 BSA-Non
Urokinase	 Sense	 BSA Only
Clone No.	 Peptide	 Peptide	 Blank
D4-C6-A8	 43,309	 946	 2,171
D4-C6-E12	 82,320	 1,405	 1,055
D4-C6-F7	 68,513	 1,280	 868
D4-C6-G12	 43,013	 1,109	 781
Note:
Group A; mice were immunized with free peptide 153-162 (Seq. ID No. 15)
Group C; mice were immunized with free peptide 154-163 (Seq. ID No. 14)
Group D; mice were immunized with BSA-conjugated peptide 154-163
(Seq. ID No. 14)
Example IV
Comparison of Prior Art Test for Urokinase with that
of Invention
Comparison of three assay methods for measuring uroki-
nase in supernatants from kidney cell cultures were made in
order to test the efficacy of the methods and compositions of
the invention with those of the prior art. Cell cultures of HEK
cells were prepared as described previously above and super-
natants of the cultures were isolated. The supernatants were
divided into aliquots for standardization runs, and runs using
one of the three test methods.
The S-244 method used a chromatogenic substrate to mea-
sure active urokinase. The method used was that of Claeson,
G. et al., "Methods for Determination of Prekalikrein in
plasma, Glandular Kallikrein, and Urokinase," Haemostasis
7:76-87 (1978), incorporated specifically herein to the extent
that it provides materials and methods not otherwise provided
herein. The microclot lysis assay ("MCLA") assay measures
the optical density of the clots being lysed by the urokinase to
determine the half-lysis time for standard concentrations. The
method used was that of Lewis et al., "A Miniaturized Fibrin-
olytic Assay for Plasminogen Activators," Thrombosis Res.
64:223-234 (1991), incorporated specifically herein to the
extent that it provides materials and methods not otherwise
provided herein.
The molecular-specific antibody ("MSA") assay of the
invention has been previously described. It is typically run as
an RIA ("MSA(RIA)") method (although it can also be an
ELISA assay or other non-radioactive assay) using antibodies
which are specific for the intact region of the active site
(158-159) on the urokinase molecule. The RIA methods uti-
lized were similar to those previously described above for the
screening of supernatants for anti-UK antibodies using solid-
phase assays (Sakata andAtassi 1981, as modifiedby Schmitz
et al. 1982). While it is possible to label either the supernatant
proteins to be tested or to label the antibodies, the inventors
typically label the antibodies as previously described.
All assays were calibrated against an international refer-
ence standard for urokinase (IRP-UK; National Biologics
Standards Board, London). A typical standard curve for the
RIA assay (specifically, those used to standardize values
observed for the Run 4 Day 12 supernatants below) is shown
in FIG. 1. That standard curve plots the results from three
separate standard assays as net counts per minute versus
microgram concentrations of urokinase in 50 microliter vol-
50
55
60
65 UmeS.
FIG. 2 is a graph comparing the amount of scuPA in the
Run 4 Day 12 supernatants using the differential S-2444
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assay, the MCLA assay, and the MSA(RIA) method of the
invention. The amount of scuPA contained in the supernatant
culture medium harvested from four (4) day old cultures of
human kidney cells, which cells had been separated by con-
tinuous flow electrophoresis into twenty-four (24) subpopu-
lations, were determined. The estimates of scuPA found by
the S-2444 assay were obtained by using two different ali-
quots of the supernatant and subtracting the levels of uPA
activity found in the S-2444 assay (direct) and the levels
found in the S-2444 assay following pre-incubation with 15
nM plasmin (2 hours at 37° C.), (which converts all of the
scuPA to active two-chain uPA). This shows that the pre-
incubation with plasma misses a significant amount of scuPA
which is actually present in the culture medium. Conversely,
the MSA is sensitive enough to measure it directly. Similarly,
the MCLA assays routinely detected far less of the scuPA than
did the MSA(RIA) methods of the invention.
Typically, the MCLA assay is the most comparable to the
MSA(RIA) assay. Thus, for instance as can be seen in super-
natant fraction 24, the two values are almost identical. Con-
versely, both the MCLA and the MSA(RIA) methods rou-
tinely detect substantially higher levels of scuPA than does
the S-2444 assay. This was not always the case, however,
since, for instance, in supernantant fractions 2-4, the S-2444
assay detected slightly more scuPA than did the MCLA assay.
18
However, in all instances, the MSA(RIA) assays of the inven-
tion were able to detect substantially higher levels of scuPA
than the two prior art approaches.
The present invention has been described in terms of par-
s ticular embodiments found or proposed to comprise preferred
modes for the practice of the invention. It will be appreciated
by those of skill in the art that, in light of the present disclo-
sure, numerous modifications and changes can be made in the
10 particular embodiments exemplified without departing from
the intended scope of the invention. For example, the anti-
body preparations of the invention would be useful for whole
body imaging techniques to look for tumors with elevated
local concentrations of urokinase. Immunotoxins based on
15 these antibody preparations would likewise be useful. Frag-
ments such as Fab or Fv derived from the invention antibodies
will find use in certain instances, as well. The peptides might
also be used as cancer vaccines to activate the human immune
system against tumors expressing urokinase. Additionally,
20 immunoaffinity columns may be constructed with the dis-
criminating antibodies of the invention to quantitate the dif-
ferent forms of urokinase in a sample (e.g., See, Sibley, et al.,
Biotechniques Vol. 10, 1993; Universal Sensors, Metairie,
La.). All such modifications are intended to be included
within the scope of the appended claims.
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 17
<210> SEQ ID NO 1
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 1
Arg Gly Lys Ala Ser Thr Asp Thr Met Gly Arg Pro Cys Leu Pro
1	 5	 10	 15
<210> SEQ ID NO 2
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 2
Arg Gly Lys Ala Ser Thr Asp Thr Met Gly Arg Pro Cys Leu Pro
1	 5	 10	 15
<210> SEQ ID NO 3
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 3
Cys Arg Asn Pro Asp Asn Arg Arg Arg Pro
1	 5	 10
<210> SEQ ID NO 4
<211> LENGTH: 11
<212> TYPE: PRT
US 7,541,159 B2
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-continued
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 4
Arg Asn Pro Asp Asn Arg Arg Arg Pro Trp Cys
1	 5	 10
<210> SEQ ID NO 5
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 5
Cys Met Val His Asp Gly Ala Asp Gly Lys
1	 5	 10
<210> SEQ ID NO 6
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 6
Met Val His Asp Cys Ala Asp Gly Lys
1	 5
<210> SEQ ID NO 7
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 7
Tyr Arg Arg His Arg Gly Gly Ser Val Thr Tyr Val Cys
1	 5	 10
<210> SEQ ID NO 8
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 8
Cys Phe Ile Asp Tyr Pro Lys Lys Glu Asp Tyr
1	 5	 10
<210> SEQ ID NO 9
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 9
Ser Arg Leu Asn Ser Asn Thr Gln Gly Glu Met Lys
1	 5	 10
<210> SEQ ID NO 10
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial
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-continued
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 10
Ser Met Tyr Asn Asp Pro Gin Phe Gly Thr Ser Cys
1	 5	 10
<210> SEQ ID NO 11
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 11
Leu Ile Ser His Arg Glu Cys Gin Gin Pro His Tyr Tyr Gly Ser Glu
1	 5	 10	 15
Val Thr Thr Thr Lys Met Leu Cys
20
<210> SEQ ID NO 12
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 12
Ser His Thr Lys Glu Glu Asn Gly Leu Ala Leu
1	 5	 10
<210> SEQ ID NO 13
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 13
Pro Arg Phe Lys Ile Ile Gly
1	 5
<210> SEQ ID NO 14
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 14
Arg Pro Arg Phe Lys Ile Ile Gly Gly Glu
1	 5	 10
<210> SEQ ID NO 15
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 15
Leu Arg Pro Arg Phe Lys Ile Ile Gly Gly
1	 5	 10
<210> SEQ ID NO 16
<211> LENGTH: 411
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-continued
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 16
Ser Asn Glu Leu His Gin Val Pro Ser Asn Cys Asp Cys Leu Asn Gly
1	 5	 10	 15
Gly Thr Cys Val Ser Asn Lys Tyr Phe Ser Asn Ile His Trp Cys Asn
20	 25	 30
Cys Pro Lys Lys Phe Gly Gly Gin His Cys Glu Ile Asp Lys Ser Lys
35	 40	 45
Thr Cys Tyr Glu Gly Asn Gly His Phe Tyr Arg Gly Lys Ala Ser Thr
50	 55	 60
Asp Thr Met Gly Arg Pro Cys Leu Pro Trp Asn Ser Ala Thr Val Leu
65	 70	 75	 80
Gin Gin Thr Tyr His Ala His Arg Ser Asp Ala Leu Gin Leu Gly Leu
85	 90	 95
Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Asn Arg Arg Arg Pro Trp
100	 105	 110
Cys Tyr Val Gin Val Gly Leu Lys Pro Leu Val Gin Glu Cys Met Val
115	 120	 125
His Asp Cys Ala Asp Gly Lys Lys Pro Ser Ser Pro Pro Glu Glu Leu
130	 135	 140
Lys Phe Gin Cys Gly Gin Lys Thr Leu Arg Pro Arg Phe Lys Ile Ile
145	 150	 155	 160
Gly Gly Glu Phe Thr Thr Ile Glu Asn Gin Pro Trp Phe Ala Ala Ile
165	 170	 175
Tyr Arg Arg His Arg Gly Gly Ser Val Thr Tyr Val Cys Gly Gly Ser
180	 185	 190
Leu Ile Ser Pro Cys Trp Val Ile Ser Ala Thr His Cys Phe Ile Asp
195	 200	 205
Tyr Pro Lys Lys Glu Asp Tyr Ile Val Tyr Leu Gly Arg Ser Arg Leu
210	 215	 220
Asn Ser Asn Thr Gin Gly Glu Met Lys Phe Glu Val Glu Asn Leu Ile
225	 230	 235	 240
Leu His Lys Asp Tyr Ser Ala Asp Thr Leu Ala His His Asn Asp Ile
245	 250	 255
Ala Leu Leu Lys Ile Arg Ser Lys Glu Gly Arg Cys Ala Gin Pro Ser
260	 265	 270
Arg Thr Ile Gin Thr Ile Cys Leu Pro Ser Met Tyr Asn Asp Pro Gin
275	 280	 285
Phe Gly Thr Ser Cys Glu Ile Thr Gly Phe Gly Lys Glu Asn Ser Thr
290	 295	 300
Asp Tyr Leu Tyr Pro Glu Gin Leu Lys Met Thr Val Val Lys Leu Ile
305	 310	 315	 320
Ser His Arg Glu Cys Gin Gin Pro His Tyr Tyr Gly Ser Glu Val Thr
325	 330	 335
Thr Lys Met Leu Cys Ala Ala Asp Pro Gin Trp Lys Thr Asp Ser Cys
340	 345	 350
Gin Gly Asp Ser Gly Gly Pro Leu Val Cys Ser Leu Gin Gly Arg Met
355	 360	 365
Thr Leu Thr Gly Ile Val Ser Trp Gly Arg Gly Cys Ala Leu Lys Asp
370	 375	 380
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26
-continued
Lys Pro Gly Val Tyr Thr Arg Val Ser His Phe Leu Pro Trp Ile Arg
385	 390	 395	 400
Ser His Thr Lys Glu Glu Asn Gly Leu Ala Leu
405	 410
<210> SEQ ID NO 17
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Peptide
<400> SEQUENCE: 17
Ala Asp Asp Gly Lys Lys Pro Ser Ser
1	 5
What is claimed is:
1. A method of determining total urokinase concentration
in a sample containing at least one of an active or inactive
form of urokinase, comprising:
generating at least one immunological composition
directed against at least one of a first peptide with SEQ
ID NOs: 1, 2, 3, 4, 5 or 6;
generating at least one immunological composition
directed against at least one of a second peptide with
SEQ ID NOs: 7, 8, 9, 10, 11 or 12; and
generating at least one immunological composition
directed against at least one of a third peptide with SEQ
ID NOs: 13 or 14;
contacting aliquots of said sample separately with each of
said at least one immunological composition; and
measuring quantity and comparing type of said at least one
immunological composition bound in each of said ali-
quots to determine a concentration of said at least one of
said active or inactive form of urokinase, wherein each
of said at least one immunological composition binds to
said at least one of said active or inactive form of uroki-
nase and is indicative of said concentration of the form
that is bound thereto, wherein the total of said concen-
tration of said at least one of said active and inactive
form of urokinase represents the total urokinase concen-
tration in said sample.
2. The method of claim 1, wherein each of said at least one
immunological composition has a binding affinity constant
for said first peptide, said second peptide or said third peptide
against which it is directed that is substantially higher than its
binding affinity constant for a non-urokinase protein as simi-
lar in amino acid sequence to urokinase as is trypsin.
3. The method of claim 1, wherein said at least one immu-
nological composition directed against a third peptide with
SEQ ID NO: 14 exhibits a binding affinity constant for uroki-
nase zymogen, an inactive form of urokinase, of at least 1 x1 0"
M-1 and a binding affinity constant for forms of urokinase
lacking a peptide bond between amino acid residues 158 and
159 of Seq ID No. 16 of at least approximately 10-fold lower
than that for urokinase zymogen.
4. The method of claim 1, wherein said at least one immu-
nological composition is an antiserum, an antibody, or a
supernatent of a hybridoma.
5. The method of claim 1, wherein said determination of
said quantity of each of said at least one immunological
composition is carried out by radiolabeling said sample.
20	 6. The method of claim 1, wherein said at least one active
or inactive form of urokinase comprises:
• low molecular weight urokinase that is bound to said at
least one immunological composition directed against
25 said second peptide but is not bound to said at least one
immunological composition directed against said first
peptide;
• high molecular weight urokinase that is bound to said at
least one immunological composition directed against
30 said first peptide or second peptide but is not bound to
said at least one immunological composition directed
against said third peptide; and
• urokinase zymogen, an inactive form of urokinase that is
bound to said at least one immunological composition
35	 directed against said third peptide.
7. The method of claim 1, wherein said step of generating
at least one immunological composition is further comprised
of generating at least one immunological composition
directed against a fourth peptide with SEQ ID NO: 17.
40 8. The method of claim 7, wherein said at least one of said
active or the inactive form of urokinase comprises a low
molecular weight urokinase that is bound to said at least one
of said immunological composition directed against said sec-
ond peptide, but is not bound to said immunological compo-
45 sition directed against said fourth peptide; and a high molecu-
larweight urokinase in the sample that is bound to said at least
one immunological composition directed against said first
peptide or said second peptide, but is not bound to said immu-
nological composition directed against said third peptide.
50 9. A method of determining total urokinase concentration
in a sample containing at least one of an active or inactive
form of urokinase, comprising:
generating at least one immunological composition
selected from a group of immunological compositions
55 consisting of an antisera, an antibody and a supernatant
of a hybridoma, each of said at least one immunological
composition obtained via injection of at least one of a
first peptide with SEQ ID NOs: 1, 2, 3, 4, 5 or 6;
generating at least one immunological composition
60 selected from a group of immunological compositions
consisting of an antisera, an antibody and a supernatant
of a hybridoma, each of said at least one immunological
composition obtained via injection of at least one of a
second peptide with SEQ ID NOs: 7, 8, 9, 10, 11 or 12;
65	 and
generating at least one immunological composition
selected from a group of immunological compositions
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consisting of an antisera, an antibody and a supernatant
of a hybridoma, each of said at least one immunological
composition obtained via injection of at least one of a
third peptide with SEQ ID NOs: 13 or 14;
contacting aliquots of said sample separately with each of
said at least one immunological composition;
measuring quantity and comparing type of each of said at
least one immunological composition bound in each of
said aliquot to determine a total concentration of said at
least one of said active and inactive form of urokinase in
said sample, wherein each of said at least one immuno-
logical composition binds to said at least one of said
active or inactive forms of urokinase and is indicative of
said total concentration of the form of urokinase that is
bound thereto, said determination comprising:
determining a first concentration of low molecular weight
urokinase in said sample, wherein said low molecular
weight urokinase is bound to said at least one immuno-
logical composition directed against said second pep-
tide, but is not bound to said at least one immunological
composition directed against said first peptide;
determining a second concentration of high molecular
weight urokinase in said sample, wherein said high
molecular weight urokinase is bound to said at least one
immunological composition directed against said first
peptide or second peptide, but is not bound to said at
least one immunological composition directed against
said third peptide, and
determining a third concentration of urokinase zymogen,
an inactive form of urokinase, in said sample, wherein
28
said urokinase zymogen is bound to said at least one
immunological composition directed against said third
peptide; and
adding the first, second and third concentrations to obtain
5 said total concentration, wherein said total concentra-
tion represents a total urokinase concentration in said
sample.
10.A kit for determining total urokinase concentration in a
sample containing at least one of an active or inactive form of
io urokinase, comprising:
immunological compositions) directed against at least one
of a first peptide with SEQ ID NOs: 1, 2, 3, 4, 5, or 6;
immunological compositions) directed against at least one
of a second peptide with SEQ ID NOs: 7, 8, 9, 10, 11 or
15	 12;
immunological compositions) directed against at least one
of a third peptide with SEQ ID NOs: 13 or 14; and
instructions for determining said total urokinase concen-
tration in said sample by adding concentrations of said at
20 least one of said active and inactive forms of urokinase
obtained by measuring quantity and type of immuno-
logical compositions) bound in aliquots of said sample.
11. The kit of claim 10, wherein said immunological com-
positions) is further comprised of:
25	 an immunological composition directed against a fourth
peptide with SEQ ID NO: 17.
12. The kit of claim 10, wherein said immunological com-
positions) is an antiserum, an antibody or a supernatant of a
hybridoma.
